{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:13:02Z","timestamp":1780391582522,"version":"3.54.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02279-8","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:19:00Z","timestamp":1776439140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle"],"prefix":"10.1186","volume":"28","author":[{"given":"Per E.","family":"L\u00f8nning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksii","family":"Nikolaienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stian","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"5","key":"2279_CR1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"CL Hu","year":"2021","unstructured":"Hu CL, Hart SN, Gnanaolivu R, Huang HY, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351.","journal-title":"N Engl J Med"},{"issue":"3","key":"2279_CR2","doi-asserted-by":"crossref","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","volume":"8","author":"N Mavaddat","year":"2022","unstructured":"Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022;8(3):e216744.","journal-title":"JAMA Oncol"},{"issue":"9","key":"2279_CR3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","volume":"35","author":"L Arecco","year":"2024","unstructured":"Arecco L, Bruzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, et al. Impact of hormone receptor status and tumor subtypes of breast cancer in young\u2009<\u2009i> BRCA carriers. Ann Oncol. 2024;35(9):792\u2013804.","journal-title":"Ann Oncol"},{"key":"2279_CR4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.humpath.2018.10.005","volume":"84","author":"IMH Sonderstrup","year":"2019","unstructured":"Sonderstrup IMH, Jensen MBR, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, et al. Subtypes in BRCA-mutated breast cancer. Hum Pathol. 2019;84:192\u2013201.","journal-title":"Hum Pathol"},{"issue":"6","key":"2279_CR5","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","volume":"10","author":"W Foulkes","year":"2004","unstructured":"Foulkes W, Metcalfe K, Sun P, Hanna W, Lynch H, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10(6):2029\u201334.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2279_CR6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"A Kurian","year":"2019","unstructured":"Kurian A, Ward K, Howlader N, Deapen D, Hamilton A, Mariotto A, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305\u2013.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2279_CR7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.annonc.2024.07.244","volume":"35","author":"CF Rowlands","year":"2024","unstructured":"Rowlands CF, Allen S, Balma\u00f1a J, Domchek SM, Evans DG, Hanson H, et al. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Ann Oncol. 2024;35(10):892\u2013901.","journal-title":"Ann Oncol"},{"key":"2279_CR8","doi-asserted-by":"crossref","unstructured":"Azim H, Elghazawy H, Shohdy K, Lasheen S, Elghazawy M, Ghazy R et al. Impact of BRCA mutation on treatment outcomes of endocrine therapy\u2009\u00b1\u2009CDK4\/6 inhibitors in hormone receptor-positive\/human epidermal growth factor receptor-2-negative breast cancer: a systematic review and meta-analysis. Jco Precision Oncol. 2025;9.","DOI":"10.1200\/PO-24-00841"},{"issue":"10","key":"2279_CR9","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","volume":"25","author":"J Staaf","year":"2019","unstructured":"Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reutersward C, Hakkinen J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25(10):1526\u2013.","journal-title":"Nat Med"},{"issue":"43","key":"2279_CR10","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","volume":"25","author":"NC Turner","year":"2006","unstructured":"Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846\u201353.","journal-title":"Oncogene"},{"issue":"1","key":"2279_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reutersward C, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020;11(1):1\u201315.","journal-title":"Nat Commun"},{"key":"2279_CR12","doi-asserted-by":"crossref","unstructured":"Nikolaienko O, Eikesdal HP, Ognedal E, Gilje B, Lundgren S, Blix ES et al. Prenatal\u2009<\u2009i>BRCA1 epimutations contribute significantly to triple-negative breast cancer development. Genome Med. 2023;15(1).","DOI":"10.1186\/s13073-023-01262-8"},{"issue":"e2400746","key":"2279_CR13","first-page":"1","volume":"9","author":"PE L\u00f8nning","year":"2025","unstructured":"L\u00f8nning PE, Nikolaienko O, Knappskog S. Constitutional epimutations: from rare events toward major cancer risk factors? Jco Precision Oncol. 2025;9(e2400746):1\u201312.","journal-title":"Jco Precision Oncol"},{"key":"2279_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00906-3","author":"J Pasanisi","year":"2026","unstructured":"Pasanisi J, Lamy C, Lecompte L, Vacher S, Schwartz M, Hamza A, et al. Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer. NPJ Breast Cancer. 2026. https:\/\/doi.org\/10.1038\/s41523-026-00906-3.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"2279_CR15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15698\/cst2019.04.183","volume":"3","author":"PE L\u00f8nning","year":"2019","unstructured":"L\u00f8nning PE, Eikesdal HP, Loes IM, Knappskog S. Constitutional Mosaic Epimutations - a hidden cause of cancer? Cell Stress. 2019;3(4):118\u201335.","journal-title":"Cell Stress"},{"key":"2279_CR16","doi-asserted-by":"crossref","unstructured":"MCGUIRE W, Breast-cancer prognostic, factors - evaluation, guidelines. J Natl Cancer Inst. 1991;83(3):154\u20135.","DOI":"10.1093\/jnci\/83.3.154"},{"key":"2279_CR17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"J Harvey","year":"1999","unstructured":"Harvey J, Clark G, Osborne C, Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474\u201381.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2279_CR18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-021-06148-0","volume":"188","author":"F Fei","year":"2021","unstructured":"Fei F, Siegal G, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Res Treat. 2021;188(1):225\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"2279_CR19","first-page":"4289","volume":"38","author":"WL McGuire","year":"1978","unstructured":"McGuire WL. Steroid receptors in human breast cancer. Cancer Res. 1978;38:4289\u201391.","journal-title":"Cancer Res"},{"issue":"2","key":"2279_CR20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/1078-0432.CCR-24-1553","volume":"31","author":"A Rios-Hoyo","year":"2025","unstructured":"Rios-Hoyo A, Xiong K, Dai JW, Yau C, Marczyk M, Garcia-Milian R, et al. Hormone receptor-positive HER2-Negative\/MammaPrint high-2 breast cancers closely resemble triple-negative breast cancers. Clin Cancer Res. 2025;31(2):403\u201313.","journal-title":"Clin Cancer Res"},{"key":"2279_CR21","doi-asserted-by":"crossref","unstructured":"Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1\u201310% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729\u201334.","DOI":"10.1200\/JCO.2011.36.2574"},{"key":"2279_CR22","doi-asserted-by":"crossref","unstructured":"L\u00e6nkholm A, Jensen M, Eriksen J, Rasmussen B, Knoop A, Buckingham W, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018;36(8):735\u2013.","DOI":"10.1200\/JCO.2017.74.6586"},{"issue":"24","key":"2279_CR23","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1158\/1078-0432.CCR-20-1923","volume":"26","author":"W Schroth","year":"2020","unstructured":"Schroth W, Buttner FA, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, et al. Gene expression signatures of brcaness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients. Clin Cancer Res. 2020;26(24):6523\u201334.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2279_CR24","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/ijc.30616","volume":"140","author":"N Halpern","year":"2017","unstructured":"Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, et al. Oncotype Dx recurrence score among BRCA1\/2 germline mutation carriers with hormone receptors positive breast cancer. Int J Cancer. 2017;140(9):2145\u20139.","journal-title":"Int J Cancer"},{"key":"2279_CR25","doi-asserted-by":"crossref","unstructured":"Yoder R, Kimler B, Staley J, Schwensen K, Wang Y, Finke K et al. Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. Npj Breast Cancer. 2022;8(1).","DOI":"10.1038\/s41523-022-00448-4"},{"issue":"22","key":"2279_CR26","first-page":"4987","volume":"57","author":"R Clarke","year":"1997","unstructured":"Clarke R, Howell A, Potten C, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997;57(22):4987\u201391.","journal-title":"Cancer Res"},{"issue":"6","key":"2279_CR27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/bcr938","volume":"6","author":"D Allred","year":"2004","unstructured":"Allred D, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004;6(6):240\u20135.","journal-title":"Breast Cancer Res"},{"issue":"14","key":"2279_CR28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1775","volume":"291","author":"G Anderson","year":"2004","unstructured":"Anderson G, Limacher M, Assaf A, Bassford T, Beresford S, Black H, et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - the women\u2019s health initiative randomized controlled trial. Jama-Journal Am Med Association. 2004;291(14):1701\u201312.","journal-title":"Jama-Journal Am Med Association"},{"issue":"16","key":"2279_CR29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/jnci\/djg022","volume":"95","author":"TJ Key","year":"2003","unstructured":"Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218\u201326.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2279_CR30","first-page":"2127","volume":"71","author":"IC Henderson","year":"1992","unstructured":"Henderson IC. Risk factors for breast cancer development. Cancer suppl. 1992;71(6):2127\u201340.","journal-title":"Cancer suppl"},{"key":"2279_CR31","doi-asserted-by":"crossref","unstructured":"Stoer NC, Vangen S, Singh D, Fortner RT, Hofvind S, Ursin G et al. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. Br J Cancer. 2024.","DOI":"10.1038\/s41416-024-02590-1"},{"issue":"6","key":"2279_CR32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/1055-9965.EPI-24-1181","volume":"34","author":"BT Ogbenna","year":"2025","unstructured":"Ogbenna BT, He X, Wu AH, Le Marchand L, Wilkens LR, Butler J, et al. Healthy lifestyle index and breast cancer risk among postmenopausal women: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2025;34(6):875\u201384.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2279_CR33","doi-asserted-by":"crossref","unstructured":"Xu S, Murtagh S, Han YN, Wan F, Toriola AT. Breast cancer incidence among US women aged 20\u201349 years by race, stage, and hormone receptor status. Jama Netw Open. 2024;7(1).","DOI":"10.1001\/jamanetworkopen.2023.53331"},{"issue":"12","key":"2279_CR34","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1055-9965.EPI-16-0427","volume":"25","author":"M Valla","year":"2016","unstructured":"Valla M, Vatten LJ, Engstrom MJ, Haugen OA, Akslen LA, Bjorngaard JH, et al. Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1625\u201334.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2279_CR35","doi-asserted-by":"crossref","unstructured":"Li NHY, Li CI. Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and age. Jama Netw Open. 2025;8(1).","DOI":"10.1001\/jamanetworkopen.2024.56142"},{"issue":"6","key":"2279_CR36","first-page":"477","volume":"74","author":"A Giaquinto","year":"2024","unstructured":"Giaquinto A, Sung H, Newman L, Freedman R, Smith R, Star J, et al. Breast cancer statistics 2024. Ca-a Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"Ca-a Cancer J Clin"},{"key":"2279_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.reprotox.2014.12.015","volume":"54","author":"SL Teitelbaum","year":"2015","unstructured":"Teitelbaum SL, Belpoggi F, Reinlib L. Advancing research on endocrine disrupting chemicals in breast cancer: expert panel recommendations. Reprod Toxicol. 2015;54:141\u20137.","journal-title":"Reprod Toxicol"},{"issue":"8","key":"2279_CR38","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1097\/JS9.0000000000002642","volume":"111","author":"Y Hong","year":"2025","unstructured":"Hong Y, Li J, Du Z, Xu N, Yang Q, Zhou J, et al. Genomic evidence based on eQTL data implicates endocrine disruptors as environmental risk factors for estrogen receptor-positive breast cancer. Int J Surg. 2025;111(8):5664\u201374.","journal-title":"Int J Surg"},{"issue":"1","key":"2279_CR39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/me.2004-0488","volume":"20","author":"YX Ma","year":"2006","unstructured":"Ma YX, Katiyar P, Jones LP, Fan SJ, Zhang YY, Furth PA, et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol. 2006;20(1):14\u201334.","journal-title":"Mol Endocrinol"},{"issue":"7","key":"2279_CR40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bjc.6603042","volume":"94","author":"M Bramley","year":"2006","unstructured":"Bramley M, Clarke RB, Howell A, Evans DGR, Armer T, Baildam AD, et al. Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer. 2006;94(7):1021\u20138.","journal-title":"Br J Cancer"},{"issue":"6","key":"2279_CR41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","volume":"26","author":"E Blondeaux","year":"2025","unstructured":"Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim H, Franzoi M, et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 2025;26(6):759\u201370.","journal-title":"Lancet Oncol"},{"key":"2279_CR42","doi-asserted-by":"crossref","unstructured":"Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K et al. Breast cancer risk and breast-cancer-specific mortality following risk-reducing salpingo-oophorectomy in BRCA carriers: a systematic review and meta-analysis. Cancers. 2023;15(5).","DOI":"10.3390\/cancers15051625"},{"key":"2279_CR43","doi-asserted-by":"crossref","unstructured":"Heemskerk-Gerritsen B, Seynaeve C, van Asperen C, Ausems M, Collee J, van Doorn H et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction. Jnci-Journal Natl Cancer Inst. 2015;107(5).","DOI":"10.1093\/jnci\/djv033"},{"issue":"3","key":"2279_CR44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-025-07821-4","volume":"214","author":"C Willert","year":"2025","unstructured":"Willert C, Mellemkj\u00e6r L, Tolver A, Gerdes A, Rosthoj S, Wadt K, et al. Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1\/2 carriers: a population-based study with matched controls. Breast Cancer Res Treat. 2025;214(3):355\u201366.","journal-title":"Breast Cancer Res Treat"},{"key":"2279_CR45","unstructured":"Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Nogues C et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. 2020;22, art 8(1):1\u201311."},{"issue":"4","key":"2279_CR46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaoncol.2023.6937","volume":"10","author":"J Kotsopoulos","year":"2024","unstructured":"Kotsopoulos J, Gronwald J, Huzarski T, Moller P, Pal T, McCuaig JM, et al. Bilateral oophorectomy and all-cause mortality in women with <\u2009i>BRCA1\u2009and BRCA2 sequence variations. JAMA Oncol. 2024;10(4):484\u201392.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2279_CR47","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331\u20137.","journal-title":"J Clin Oncol"},{"issue":"9245","key":"2279_CR48","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356(9245):1876\u201381.","journal-title":"Lancet"},{"issue":"25","key":"2279_CR49","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"K Phillips","year":"2013","unstructured":"Phillips K, Milne R, Rookus M, Daly M, Antoniou A, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091\u20139.","journal-title":"J Clin Oncol"},{"issue":"5797","key":"2279_CR50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","volume":"314","author":"T Sj\u00f8blom","year":"2006","unstructured":"Sj\u00f8blom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268\u201374.","journal-title":"Science"},{"issue":"7132","key":"2279_CR51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","volume":"446","author":"C Greenman","year":"2007","unstructured":"Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153\u20138.","journal-title":"Nature"},{"key":"2279_CR52","doi-asserted-by":"crossref","unstructured":"Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571(7766):576.","DOI":"10.1038\/s41586-019-1382-1"},{"key":"2279_CR53","doi-asserted-by":"crossref","unstructured":"Rajagopal PS, Hassan S, Pritchard CC. Hotspot BRCA1\/2 mutations in tumors with microsatellite instability suggest passenger mutation status and evaluation of therapeutic options. Jco Precision Oncol. 2025;9.","DOI":"10.1200\/PO-25-00141"},{"issue":"1","key":"2279_CR54","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134\u201347.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"2279_CR55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou XQ, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517\u2013.","journal-title":"Nat Med"},{"issue":"7605","key":"2279_CR56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Dominik, Zou XQ, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u2013.","journal-title":"Nature"},{"issue":"13","key":"2279_CR57","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1158\/0008-5472.CAN-24-2639","volume":"85","author":"A Abbasi","year":"2025","unstructured":"Abbasi A, Steele C, Bergstrom E, Khandekar A, Farswan A, McKay R, et al. HRProfiler detects homologous recombination deficiency in breast and ovarian cancers using whole-genome and whole-exome sequencing data. Cancer Res. 2025;85(13):2504\u201313.","journal-title":"Cancer Res"},{"issue":"7","key":"2279_CR58","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-21-2080","volume":"28","author":"JL Blum","year":"2022","unstructured":"Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, et al. Determinants of response to talazoparib in patients with HER2-negative, Germline BRCA1\/2-mutated breast cancer. Clin Cancer Res. 2022;28(7):1383\u201390.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2279_CR59","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.annonc.2021.08.2154","volume":"32","author":"D Hodgson","year":"2021","unstructured":"Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, et al. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann Oncol. 2021;32(12):1582\u20139.","journal-title":"Ann Oncol"},{"key":"2279_CR60","doi-asserted-by":"crossref","unstructured":"Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Wesseling J, Vijver MJV et al. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014;16(3).","DOI":"10.1186\/bcr3655"},{"key":"2279_CR61","doi-asserted-by":"crossref","first-page":"e2300338","DOI":"10.1200\/PO.23.00338","volume":"7","author":"S Yndestad","year":"2023","unstructured":"Yndestad S, Engebrethsen C, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestol RK, et al. Homologous recombination deficiency across subtypes of primary breast cancer. JCO Precis Oncol. 2023;7:e2300338.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"2279_CR62","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2279_CR63","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628\u2013.","journal-title":"Nat Med"},{"issue":"1","key":"2279_CR64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","volume":"32","author":"L Tobalina","year":"2021","unstructured":"Tobalina L, Armenia J, Irving E, O\u2019Connor MJ, Forment JV. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2021;32(1):103\u201312.","journal-title":"Ann Oncol"},{"issue":"1","key":"2279_CR65","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/bcr1858","volume":"10","author":"C Snell","year":"2008","unstructured":"Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008;10(1):R12. https:\/\/doi.org\/10.1186\/bcr1858.","journal-title":"Breast Cancer Res"},{"issue":"19","key":"2279_CR66","first-page":"5329","volume":"60","author":"RL Baldwin","year":"2000","unstructured":"Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60(19):5329\u201333.","journal-title":"Cancer Res"},{"issue":"11","key":"2279_CR67","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/jamaoncol.2022.3846","volume":"8","author":"PE L\u00f8nning","year":"2022","unstructured":"L\u00f8nning PE, Nikolaienko O, Pan K, Kurian AW, Eikesdal HP, Pettinger M, et al. Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. JAMA Oncol. 2022;8(11):1579\u201387.","journal-title":"JAMA Oncol"},{"issue":"7","key":"2279_CR68","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/cas.70078","volume":"116","author":"S Tsuchimochi","year":"2025","unstructured":"Tsuchimochi S, Yamamoto Y, Taguchi A, Kawazu M, Sone K, Ikemura M, et al. BRCA1 promoter methylation in ovarian cancer: clinical relevance and a novel diagnostic approach using fragment analysis. Cancer Sci. 2025;116(7):1996\u20132007.","journal-title":"Cancer Sci"},{"issue":"art 7353984","key":"2279_CR69","first-page":"1","volume":"2024","author":"P L\u00f8nning","year":"2024","unstructured":"L\u00f8nning P, Nikolaienko O, Knappskog S. Constitutional BRCA1 epimutations: a key for understanding basal-like breast and high-grade serous ovarian cancer. Hum Mutat. 2024;2024(art 7353984):1\u201311.","journal-title":"Hum Mutat"},{"issue":"2","key":"2279_CR70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32(2):240\u20139.","journal-title":"Ann Oncol"},{"key":"2279_CR71","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9."},{"issue":"1","key":"2279_CR72","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021;12(1):2487.","journal-title":"Nat Commun"},{"key":"2279_CR73","doi-asserted-by":"crossref","unstructured":"Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Sci Transl Med. 2022;14(652).","DOI":"10.1126\/scitranslmed.abn1926"},{"key":"2279_CR74","doi-asserted-by":"crossref","unstructured":"Nougarede L, Hazane-Puch F, de Fraipont F, Jacquet E, Bidart M. BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study. Clin Epigenetics. 2025;17(1).","DOI":"10.1186\/s13148-025-01917-w"},{"key":"2279_CR75","doi-asserted-by":"crossref","unstructured":"Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, Bowles EAJ et al. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Res. 2023;25(1).","DOI":"10.1186\/s13058-023-01647-y"},{"key":"2279_CR76","doi-asserted-by":"crossref","unstructured":"McGale P, Dodwell D, Challenger A, Cutter D, Williams A, Broggio J et al. Second cancers in 475 000 women with early invasive breast cancer diagnosed in England during 1993\u20132016: population based observational cohort study. Bmj-British Med J. 2025;390.","DOI":"10.1136\/bmj-2024-083975"},{"issue":"10","key":"2279_CR77","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras V, Han H, Kaufman B, Wildiers H, Friedlander M, Ayoub J, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(10):1269\u201382.","journal-title":"Lancet Oncol"},{"issue":"28","key":"2279_CR78","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2011.35.2682","volume":"29","author":"B Arun","year":"2011","unstructured":"Arun B, Bayraktar S, Liu D, Barrera A, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29(28):3739\u201346.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02279-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02279-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02279-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:29:34Z","timestamp":1780388974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02279-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02279-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not relevant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not relevant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}